Recent Updates
Recently added Catalysts
ACRS Positive Sentiment

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tuesday, November 26, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Aclaris Therapeutics, Inc. will participate in the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024. Members of the management team will take part in a fireside chat to discuss the company's development of novel drug candidates for immuno-inflammatory diseases. The event will provide insight into Aclaris' initiatives and can be accessed via a webcast on their website. This participation positions the company favorably among key industry stakeholders and investors.
Price reaction · baseline $3.99 (2024-11-25 close) · hit after-hours · clean, no other ACRS news in the window
day 0 close · peak
-9%
day 1
-4.3%
day 3
-0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Aclaris is participating in a prominent healthcare conference, raising visibility.
  • The company's focus on novel drug candidates aligns with current treatment needs.
  • The webcast allows for greater accessibility to Aclaris' information for investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis

Full Press Release Details

WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York.
A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics Contact:

Frequently Asked Questions

When is Aclaris Therapeutics' fireside chat?

The fireside chat is on December 3, 2024, at 1:00 PM ET.

Where can I access the webcast of the fireside chat?

The webcast can be accessed on Aclaris' website's Events page.

What type of company is Aclaris Therapeutics?

Aclaris is a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases.

How long will the webcast be available online?

The webcast will be archived for at least 30 days on Aclaris' website.

What is Aclaris' focus in drug development?

Aclaris develops novel drug candidates for patients with unmet treatment needs.

ShareAdd on Google
Tags: ACRS Viatris Investor Conferences Healthcare Aclaris Therapeutics Piper Sandler immuno-inflammatory diseases biopharmaceutical clinical-stage
Last updated: Nov 26, 2024

Biotech snapshot

Cash runway
$171M liquidity · $7M/mo burn
~25 mo
Minimal dilution risk
Lead asset
ATI-045Phase 2
Atopic Dermatitis →

Catalyst track record

+181%
best trade around ACRS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ACRS.

See every catalyst's timing & PoA →